Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Apply
AO-252
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step